Governments have decided they will pay any price in the fight against COVID-19 while the pharmaceutical sector is already grappling with supply. Nobody should expect the PBS in 2021, 2022 or beyond to look like it does in 2020 - and that is before you even consider the long-term budgetary impact of the shock about to hit the economy.
This is just the start of a challenge that will almost certainly leave a permanent 'scar'
March 21, 2020 Latest NewsComment
Latest Video
New Stories
-
GBMA moves to reclaim the reform agenda with a focus on pricing and supply
February 5, 2026 - - Latest News -
Nuclear medicine sector argues for dedicated scheme to unlock cancer therapies
February 4, 2026 - - Latest News -
Pfizer’s once-monthly weight-loss injection delivers strong mid-stage results
February 4, 2026 - - Latest News -
GBMA Summit focuses on access, affordability and security in an uncertain world
February 4, 2026 - - Latest News -
Medicines Australia calls for Budget action to restore access to innovative medicines
February 3, 2026 - - Latest News -
Survey exposes deep gaps in support for Australians living with rare cancers
February 3, 2026 - - Latest News -
Juvenile Arthritis Foundation Australia seeks new CEO as Angela McKay steps down
February 3, 2026 - - Latest News

